Sharechat Logo

Interim profit tumble

Duncan Bridgeman

Friday 14th November 2003

Text too small?
Fisher & Paykel Healthcare shares lost ground this week following a 25% fall in net profit for the six months to September.

However, a policy change in accounting for foreign exchange hedges made comparisons with the same period a year ago misleading.

F&P Healthcare shares traded early yesterday at $12.05, down 20c since the interim profit announcement on Wednesday.

While net profit fell to $25.2 million, revenue growth from new products climbed 27% in US dollar terms, pushing operating revenue up 3.8% to a record $104.9 million.

The company is forecasting full year revenue of between $US120 million ($193.5 million) and $US125 million.

ABN Amro said in a research note it was reviewing its target price of $13.14 and its add recommendation on the stock. The broking house noted that the company's new obstructive sleep apnoea (OSA) flow generators would be fully established in the second half of the current financial year while its new mask products should continue to increase consumables market sha

  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

New Bond Issue Market Looking Very Upbeat
General Capital to Broadcast Adjourned Annual Meeting
Kathmandu announces FY20 Annual Results
EROAD opens NZ$8 million Share Purchase Plan
Refinery simplification plan update
Heartland announces FY20 full year results
Geo Limited releases its FY20 Annual Report
Michael Hill International Limited announces 2020 annual report
Tower supports climate risk reporting
Tourism Holdings Limited Updated FY20 guidance

IRG See IRG research reports